Rolaids is an American brand of calcium and magnesium-based antacid produced by Chattem. It was invented by American chemist Irvine W. Grote in the late 1920s, and originated with manufacturing in Chattanooga, Tennessee, under one of Chattems forerunner companies, which manufactured the brand for Warner-Lambert; Warner-Lambert merged with Pfizer in 2000. In 2006, McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson, acquired the brand from Pfizer Consumer Healthcare. In 2013, McNeil sold the brand to Sanofi, following a two-year period where the brand was pulled off the market due to product recalls resulting from quality control and manufacturing issues that also left former fellow antacid brand Pepcid ACs "chewables" product and other fellow McNeil products like some varieties of Tylenol off store shelves for the same period. Rolaids returned to the market at the beginning of September 2013 under Chattem ownership with new packaging, trade dress, and a new liquid variety. Rolaids tablets come in many different flavors, including original peppermint, cherry, freshmint, fruit, tropical, punch, cool mint, berry, and apple. 2010 recall
McNeil Consumer Healthcare voluntarily recalled Rolaids products in the Americas, the United Arab Emirates (UAE), and Fiji on January 15, 2010, in consultation with the FDA. The company initiated the recall following an investigation of consumer reports of an unusual moldy, musty, or mildewlike odor that, in a small number of cases, was associated with temporary and nonserious gastrointestinal events. These events included nausea, stomach pain, vomiting, and diarrhea.
Goldenhar syndrome is a rare congenital defect characterized by incomplete development of the ear, nose, soft palate, lip and mandible on usually one side of the body. Common clinical manifestations include limbal dermoids, preauricular skin tags and strabismus. It is associated with anomalous development of the first branchial arch and second branchial arch.The term is sometimes used interchangeably with hemifacial microsomia, although this definition is usually reserved for cases without internal organ and vertebrae disruption. It affects between 1 in 3,500 and 1 in 5,600 live births, with a male-to-female ratio of 3:2. Signs and symptoms
Chief markers of Goldenhar syndrome are incomplete development of the ear, nose, soft palate, lip, and mandible on usually one side of the body. Additionally, some patients will have growing issues with internal organs, especially heart, kidneys and lungs. Typically, the organ will either not be present on one side or will be underdeveloped. While it is more usual for there to be problems on only one side, it has been known for defects to occur bilaterally (approximate incidence 10% of confirmed GS cases).Other problems can include severe scoliosis (twisting of the vertebrae), limbal dermoids and hearing loss (see hearing loss with craniofacial syndromes), and deafness or blindness in one or both ears/eyes. Granulosa cell tumors may be associated as well. Causes
The cause of Goldenhar syndrome is largely unknown. However, it is thought to be multifactorial, although there may be a genetic component, which would account for certain familial patterns.